Hepatitis: Monitoring drug therapy for hepatitis B - A global challenge?

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 10, 2009, Pages 565-567

  Nguyen, Tin ^a   Locarnini, Stephen ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIFE CYCLE; PATHOGENESIS; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 70349972123     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.160     Document Type: Article

References (10)

1. Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006).
2. Iloeje, U. H. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686 (2006).
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
4. Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531 (2004).
5. Zeuzem, S. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 51, 11-20 (2009).
6. Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503-1514 (2009).
7. Snow-Lampart, A. et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 MG QD [abstract 977]. Hepatology 48 (Suppl. 1), 745A (2008).
8. Bonino, F. et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56, 699-705 (2007).
9. Fried, M. W. et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47, 428-434 (2008).
10. Brunetto, M. R. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49, 1141-1150 (2009).